Table 3.
Comparisons between male and female OSA patients
| Variables | Female | Male | P value |
|---|---|---|---|
| N (%) | 148 (21.6) | 537 (78.4)* | <0.001 |
| Age (years) | 62.8 ± 10.2 | 58.4 ± 11.9* | <0.001 |
| BMI (Kg/m2) | 26.2 ± 4.2 | 25.6 ± 4.1 | 0.136 |
| SBP (mm Hg) | 139.8 ± 21.4 | 136.7 ± 21.5 | 0.111 |
| DBP (mm Hg) | 79.1 ± 15.1 | 79.4 ± 14.1 | 0.831 |
| AHI | 18.0 ± 15.4 | 23.1 ± 16.8* | 0.001 |
| IVS (mm) | 10.7 ± 1.8 | 11.6 ± 2.4* | <0.001 |
| LVPW (mm) | 9.9 ± 1.6 | 10.7 ± 1.8* | <0.001 |
| HbA1c (%) | 6.6 ± 1.4 | 6.2 ± 1.1* | 0.001 |
| Creatinine (μmol/L) | 81.7 ± 38.7 | 103.7 ± 52.2* | <0.001 |
| BUN (mmol/L) | 5.7 ± 3.5 | 5.8 ± 2.6 | 0.836 |
| FPG (mmol/L) | 7.0 ± 3.4 | 6.3 ± 2.8* | 0.015 |
| Triglyceride (mmol/L) | 1.8 ± 0.2 | 1.8 ± 0.3 | 0.619 |
| Total cholesterol (mmol/L) | 4.7 ± 1.4 | 4.5 ± 1.2* | 0.019 |
| LDL-C (mmol/L) | 2.8 ± 1.1 | 2.7 ± 0.9 | 0.092 |
| HDL-C (mmol/L) | 1.1 ± 0.3 | 1.0 ± 0.2 | 0.947 |
| Proteinuria (%) | 14.9 | 21.9 | 0.289 |
| Diabetes mellitus (%) | 33.8 | 21.8* | 0.003 |
| Dyslipidemia (%) | 23.0 | 12.3* | 0.001 |
| Aortic dissection (%) | 10.8 | 22.3* | 0.002 |
| Aneurysm (%) | 1.4 | 6.5* | 0.014 |
| CHD (%) | 37.8 | 43.0 | 0.258 |
| Cerebrovascular disease (%) | 12.8 | 9.1 | 0.181 |
| Heart failure (%) | 25.0 | 21.0 | 0.303 |
| Atrial fibrillation (%) | 12.8 | 8.0 | 0.070 |
| HCM (%) | 4.1 | 3.2 | 0.595 |
| Anti-platelet (%) | 55.4 | 54.0 | 0.762 |
| Statins (%) | 68.2 | 66.5 | 0.687 |
| ACEI (%) | 19.6 | 22.7 | 0.417 |
| ARB (%) | 43.2 | 46.7 | 0.450 |
| Beta-blocker (%) | 60.8 | 68.0 | 0.102 |
| Alpha-blocker (%) | 3.4 | 7.3 | 0.088 |
| CCB (%) | 60.8 | 56.1 | 0.300 |
| Diuretic (%) | 18.9 | 18.6 | 0.935 |
| Warfarin (%) | 10.1 | 6.3 | 0.112 |
Denote: BUN blood uria nitrogen, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CHD coronary heart disease, HCM hypertrophy cardiomyopahty, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker
*P < 0.05 versus female group